The two sides of HER2/neu: Immune escape versus surveillance

Trends in Molecular Medicine

Volumn 19, Issue 11, 2013, Pages 677-684

  Seliger, Barbara ^a   Kiessling, Rolf ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

HER2; HLA; Immune escape; Immunotherapy; Tumor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; JANUS KINASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; TRASTUZUMAB;

ADAPTIVE IMMUNITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; ONCOGENE NEU; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL; UPREGULATION;

HER2; HLA; IMMUNE ESCAPE; IMMUNOTHERAPY; TUMOR;

ANIMALS; HUMANS; IMMUNOLOGIC SURVEILLANCE; NEOPLASMS; RECEPTOR, ERBB-2; TUMOR ESCAPE;

EID: 84886949455     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.08.003     Document Type: Review

References (69)

1. Alvarez R.H., et al. Emerging targeted therapies for breast cancer. J. Clin. Oncol. 2010, 28:3366-3379.
2. Junttila T.T., et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res. 2010, 70:4481-4489.
3. Nielsen D.L., et al. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 2013, 22:1-12.
4. Clynes R.A., et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
5. Musolino A., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 2008, 26:1789-1796.
6. Varchetta S., et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 2007, 67:11991-11999.
7. Park S., et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010, 18:160-170.
8. Taylor C., et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res. 2007, 13:5133-5143.
9. Burgess A.W. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 2008, 26:263-274.
10. Marmor M.D., et al. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:903-913.
11. Warren C.M., Landgraf R. Signaling through ERBB receptors: multiple layers of diversity and control. Cell. Signal. 2006, 18:923-933.
12. Press M.F., et al. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990, 5:953-962.
13. Seol H., et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod. Pathol. 2012, 25:938-948.
14. Gilbertson R.J., et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 1997, 57:3272-3280.
15. Gorlick R., et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol. 1999, 17:2781-2788.
16. Meurer R.T., et al. Immunohistochemical expression of markers Ki-67, neun, synaptophysin, p53 and HER2 in medulloblastoma and its correlation with clinicopathological parameters. Arq. Neuropsiquiatr. 2008, 66:385-390.
17. Mineo J.F., et al. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J. Neurooncol. 2007, 85:281-287.
18. Knuefermann C., et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22:3205-3212.
19. Vajdic C.M., van Leeuwen M.T. Cancer incidence and risk factors after solid organ transplantation. Int. J. Cancer 2009, 125:1747-1754.
20. Bei R., et al. Immune responses to all ErbB family receptors detectable in serum of cancer patients. Oncogene 1999, 18:1267-1275.
21. Montgomery R.B., et al. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res. 2005, 65:650-656.
22. Norell H., et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J. Transl. Med. 2010, 8:53.
23. Mittendorf E.A., et al. Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. Expert Rev. Vaccines 2011, 10:755-774.
24. Jensen P.E. Recent advances in antigen processing and presentation. Nat. Immunol. 2007, 8:1041-1048.
25. Aptsiauri N., et al. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol. Immunother. 2008, 57:1727-1733.
26. Garrido F., et al. 'Hard' and 'soft' lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int. J. Cancer 2010, 127:249-256.
27. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol. Immunother. 2008, 57:1719-1726.
28. Seliger B., et al. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 2000, 21:455-464.
29. Cabrera C.M., et al. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 2003, 61:211-219.
30. Chang C.C., et al. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel β2-microglobulin loss-of-function in melanoma cells. J. Biol. Chem. 2006, 281:18763-18773.
31. Maleno I., et al. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol. Immunother. 2002, 51:389-396.
32. Griffioen M., et al. C-myc represses transiently transfected HLA class I promoter sequences not locus-specifically. Immunobiology 1995, 193:238-247.
33. Herrmann F., et al. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res. 2004, 64:215-220.
34. Lohmann S., et al. Multiple levels of MHC class I down-regulation by ras oncogenes. Scand. J. Immunol. 1996, 43:537-544.
35. Schiffer I.B., et al. Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. Cancer Res. 2003, 63:7221-7231.
36. Seliger B., et al. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur. J. Immunol. 1998, 28:122-133.
37. Sers C., et al. Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. Int. J. Cancer 2009, 125:1626-1639.
38. Epperson D.E., et al. Cytokines increase transporter in antigen processing-1 expression more rapidly than HLA class I expression in endothelial cells. J. Immunol. 1992, 149:3297-3301.
39. Qin Z., et al. Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. Cancer Res. 2002, 62:2856-2860.
40. Mimura K., et al. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int. J. Cancer 2011, 128:390-401.
41. Zaks T.Z., Rosenberg S.A. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 1998, 58:4902-4908.
42. Conrad H., et al. CTLs directed against HER2 specifically cross-react with HER3 and HER4. J. Immunol. 2008, 180:8135-8145.
43. Choudhury A., et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int. J. Cancer 2004, 108:71-77.
44. Maruyama T., et al. Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma. Br. J. Cancer 2010, 103:552-559.
45. Inoue M., et al. Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology 2012, 1:1104-1110.
46. Corbiere V., et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 2011, 71:1253-1262.
47. Disis M.L., et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J. Clin. Oncol. 2009, 27:4685-4692.
48. Bukur J., et al. Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J. Biol. Chem. 2010, 285:30419-30426.
49. Romero I., et al. The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells. J. Pathol. 2012, 227:367-379.
50. Bianchi F., et al. Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections. Cell Cycle 2007, 6:643-646.
51. Benavides L.C., et al. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res. 2009, 15:2895-2904.
52. Mittendorf E.A., et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2012, 118:2594-2602.
53. Weiss V.L., et al. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS ONE 2012, 7:e31962.
54. Henle A.M., et al. Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells. J. Immunol. 2013, 190:479-488.
55. Karre K., et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986, 319:675-678.
56. Okita R., et al. HER2/HER3 signaling regulates NK cell mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. J. Immunol. 2012, 188:2136-2145.
57. Bauer S., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285:727-729.
58. Mani A., et al. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res. Treat. 2009, 117:83-89.
59. Parihar R., et al. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon γ production in a subset of patients. Clin. Cancer Res. 2004, 10:5027-5037.
60. Triulzi C., et al. Antibody-dependent natural killer cell mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors. Cancer Res. 2010, 70:7431-7441.
61. Morgan R.A., et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 2010, 18:843-851.
62. Gilham D.E., et al. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol. Med. 2012, 18:377-384.
63. Maliar A., et al. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 2012, 143:1375-1384.
64. Kruschinski A., et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:17481-17486.
65. Weiner L.M., et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII. Cancer Res. 1995, 55:4586-4593.
66. Kiessling R., et al. Cellular immunity to the Her-2/neu protooncogene. Adv. Cancer Res. 2002, 85:101-144.
67. Milano F., et al. Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery. PLoS ONE 2010, 5:e12424.
68. + T cells. Cancer Res. 2003, 63:4095-4100.
69. Mendoza M.C., et al. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 2011, 36:320-328.